251 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
INCY Incyte Corporation $67.04 $14.25B N/A
Article Searches
Merck Gets CHMP Nod for Six-Week Dosing Option of Keytruda http://www.zacks.com/stock/news/357700/merck-gets-chmp-nod-for-six-week-dosing-option-of-keytruda?cid=CS-ZC-FT-357700 Mar 05, 2019 - Merck (MRK) gets CHMP recommendation for a six-week dosing schedule of Keytruda across all current monotherapy indications.
4 Toxic Stocks to Discard or Sell Short for Solid Gains http://www.zacks.com/stock/news/356949/4-toxic-stocks-to-discard-or-sell-short-for-solid-gains?cid=CS-ZC-FT-356949 Feb 26, 2019 - Overhyped toxic stocks are usually susceptible to external shocks and loaded with huge amount of debt.
Merck Gets Priority Review for Keytruda in Third-Line SCLC http://www.zacks.com/stock/news/355982/merck-gets-priority-review-for-keytruda-in-third-line-sclc?cid=CS-ZC-FT-355982 Feb 21, 2019 - Merck's (MRK) sBLA looking for approval of Keytruda monotherapy for the third-line treatment of small cell lung cancer, a difficult-to-treat cancer, gets FDA's priority review.
Merck's Keytruda Fails to Meet Endpoint in Liver Cancer Study http://www.zacks.com/stock/news/355533/mercks-keytruda-fails-to-meet-endpoint-in-liver-cancer-study?cid=CS-ZC-FT-355533 Feb 20, 2019 - Merck's (MRK) Keytruda fails a phase III study in second-line advanced hepatocellular carcinoma (HCC). It gets FDA approval for the adjuvant treatment of patients with high-risk stage III melanoma.
Merck Gets Priority Review for Keytruda Combo in Kidney Cancer http://www.zacks.com/stock/news/355193/merck-gets-priority-review-for-keytruda-combo-in-kidney-cancer?cid=CS-ZC-FT-355193 Feb 18, 2019 - Merck's (MRK) sBLA looking for approval of Keytruda plus Pfizer's Inlyta for the first-line treatment of the most common type of kidney cancer gets FDA's priority review.
Incyte Corporation (INCY) CEO Hervé Hoppenot on Q4 2018 Results - Earnings Call Transcript https://seekingalpha.com/article/4241318-incyte-corporation-incy-ceo-herve-hoppenot-q4-2018-results-earnings-call-transcript?source=feed_sector_healthcare Feb 14, 2019 - Incyte Corporation (NASDAQ:INCY) Q4 2018 Results Conference Call February 14, 2019 08:00 AM ET Company Participants Mike Booth - VP, IR Hervé Hoppenot - President and CEO Barry Flannelly - EVP, Genera
Incyte (INCY) Q4 2018 Earnings Conference Call Transcript https://www.fool.com/earnings/call-transcripts/2019/02/14/incyte-incy-q4-2018-earnings-conference-call-trans.aspx?source=iedfolrf0000001 Feb 14, 2019 - INCY earnings call for the period ending December 31, 2018.
Incyte (INCY) Q4 Earnings Miss Estimates, Revenues Beat http://www.zacks.com/stock/news/354853/incyte-incy-q4-earnings-miss-estimates-revenues-beat?cid=CS-ZC-FT-354853 Feb 14, 2019 - Incyte's (INCY) fourth-quarter earnings miss estimates but revenues beat the same on strong Jakafi sales.
Merck's Keytruda Gets FDA Priority Review for Head/Neck Cancer http://www.zacks.com/stock/news/353843/mercks-keytruda-gets-fda-priority-review-for-head-neck-cancer?cid=CS-ZC-FT-353843 Feb 12, 2019 - Merck's (MRK) supplemental biologics license application for Keytruda receives a priority review from the FDA for the first-line treatment of patients with recurrent/metastatic head and neck cancer.
Is a Disappointment in Store for Incyte (INCY) Q4 Earnings? http://www.zacks.com/stock/news/353654/is-a-disappointment-in-store-for-incyte-incy-q4-earnings?cid=CS-ZC-FT-353654 Feb 11, 2019 - Investors are looking forward to Jakafi's performance and other pipeline updates when Incyte (INCY) reports Q4 results on Feb 14.

Pages: 123456789...26

<<<Page 4>